Your browser doesn't support javascript.
loading
Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.
Jacobsen, Frederick W; Stevenson, Riki; Li, Cynthia; Salimi-Moosavi, Hossein; Liu, Ling; Wen, Jie; Luo, Quanzhou; Daris, Kristine; Buck, Lynette; Miller, Sterling; Ho, Shu-Yin; Wang, Wei; Chen, Qing; Walker, Kenneth; Wypych, Jette; Narhi, Linda; Gunasekaran, Kannan.
Afiliación
  • Jacobsen FW; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320. Electronic address: rjacobse@amgen.com.
  • Stevenson R; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Li C; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Salimi-Moosavi H; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Liu L; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Wen J; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Luo Q; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Daris K; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Buck L; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Miller S; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Ho SY; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Wang W; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Chen Q; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Walker K; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Wypych J; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Narhi L; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320.
  • Gunasekaran K; From the Biologics Optimization-Therapeutic Discovery, Clinical Immunology, and Process Development, Amgen Inc., Thousand Oaks, California 91320. Electronic address: guna.kannan@yahoo.com.
J Biol Chem ; 292(5): 1865-1875, 2017 02 03.
Article en En | MEDLINE | ID: mdl-27994062
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoglobulina G / Fragmentos Fab de Inmunoglobulinas / Fragmentos Fc de Inmunoglobulinas / Sustitución de Aminoácidos / Mutación Missense Límite: Animals / Humans Idioma: En Revista: J Biol Chem Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoglobulina G / Fragmentos Fab de Inmunoglobulinas / Fragmentos Fc de Inmunoglobulinas / Sustitución de Aminoácidos / Mutación Missense Límite: Animals / Humans Idioma: En Revista: J Biol Chem Año: 2017 Tipo del documento: Article